Keywords: Roche, Tarceva, Lung cancer, NSCLC, UK, NICE

NICE recommends Roche's Tarceva for NSCLC

Article | 10 May 2012

Print This

Having received further previously requested data from Swiss drug major Roche (ROG: SIX), the UK drugs watchdog the National Institute ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in